论文部分内容阅读
目前公认,绝经后妇女单纯应用雌激素治疗有增加子宫内膜腺癌的危险.1975年以来,许多回顾性研究指出,由于雌激素替代疗法,使子宫内膜腺癌增加了1.7～20倍.绝经后来经治疗者内膜腺癌的发生率100∶100,000/年,单纯用雌激素治疗则为500～800∶100,000.同时已有充分的证据说明,雌-孕激素周期疗法可以预防内膜腺癌的发生.在Wilford Hall医学中心5年前瞻性研究中,对鲍经后妇女曾用雌激素治疗或有或无绝经期症状者,应用孕激素应激试验以确
It is now generally acknowledged that postmenopausal women treated with estrogen alone have the potential to increase endometrial adenocarcinoma. Since 1975, many retrospective studies have shown that endometrial adenocarcinoma has increased 1.7 to 20-fold due to estrogen replacement therapy. The incidence of endometrial adenocarcinoma after menopause is 100: 100,000 / year compared to 500 to 800: 100 000 for estrogen alone.At the same time, there is sufficient evidence that estrogen-progesterone cyclotherapy can prevent endometrial gland In a 5-year prospective study at the Wilford Hall Medical Center, progestin stress tests were applied to women who had been treated with estrogen, either with or without menopause, in post-menopausal women